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Abstract
Background—Acute leukemia represents 4% of cancer cases in the United States (US) annually. 
There are over 302,000 people living with acute and chronic leukemia in the US. Treatment has 
been shown to have both positive and negative effects on health-related quality of life (HRQOL).
Objective—Examine psychometric properties of symptom and HRQOL instruments and to 
provide implications for the assessment in adults with acute leukemia relevant to clinical practice 
and future research.
Methods—Systematic literature search was conducted from 1990-2014 using electronic 
databases and manual searches. Psychometric studies were considered eligible for inclusion if 1) 
the psychometric paper was published using at least one HRQOL or symptom instrument and 2) 
adults with acute leukemia were included in the sample. Studies were excluded if the age groups 
were not adults, or if the instrument was in a language other than English.
Results—Review identified a total of 7 instruments (1 cancer generic HRQOL, 2 symptom-
related, 3 HRQOL combined with symptom questions, and 1 disease- specific). The most 
commonly used instrument was the European Organization for Research and Treatment of Cancer 
(EORTC QLQ-C30), followed by the Functional Assessment of Cancer Therapy-Fatigue (FACT-
F).
Conclusions—An acute leukemia diagnosis can have a significant impact on HRQOL. Our 
recommendations include using both a HRQOL and symptom instrument to capture patient 
experiences during and after treatment.
Implications for Practice—The availability of comprehensive, valid and reliable HRQOL and 
symptom instruments to capture the experiences of adults with acute leukemia during and 
posttreatment is limited.
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Introduction
It is estimated that 54, 270 individuals in the Unites States (US) will be diagnosed with 
leukemia in 2015 and an estimated 24,450 will die from the disease.1 Of these new cases, 
27,080 have acute lymphoblastic leukemia or acute myeloid leukemia, and 11, 910 will die 
with the disease, with the remaining being chronic leukemias1. Acute leukemia has a 5-year 
survival rate of 56% in the US.2 Newly diagnosed acute leukemia is usually treated in a 
specialized care center with an average stay of 4-6 weeks. It is common for patients to have 
fluctuating symptoms associated with the disease and its treatment such as 
myelosuppression, stomatitis, and nausea throughout their hospitalization.3,4
There is the potential to advance acute leukemia science by systematically reviewing 
symptoms that occur, solely or concurrently, during and after treatment to determine how 
health-related quality of life (HRQOL) changes over time. It is important to understand 
patient-reported symptoms and HRQOL of adults with acute leukemia to better address their 
physical and psychosocial needs. In Bryant et al,4 cancer related fatigue (CRF), depression, 
and anxiety were found to be the most prominent symptoms that interfered with HRQOL 
and activities of daily living. In that review, we found that acute leukemia and its treatment 
have a significant impact in all QOL domains; we concluded that there was a need for future 
studies focused on longitudinal research and increased minority representation4.
One common way of assessing symptoms and HRQOL is through self-reported instruments, 
measuring the outcomes at one or more points. These instruments vary in the symptoms and 
HRQOL domains measured, the length of the questionnaire, the wording of questions and 
their response options, the reference or recall period, and the level of psychometric evidence 
in support of the validity and reliability of the measure.
The majority of the measures are not leukemia specific, except for the Functional 
Assessment of Cancer Therapy-Leukemia (FACT-Leu), which was recently developed in 
2002.5
This review examined the psychometric properties of instruments used in acute leukemia 
research, and provides clinical and research relevant implications of symptom and HRQOL 
instruments used in adults with acute leukemia.
Methods
Search strategy
Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) guidelines6, a systematic literature search was conducted by the first (ALB) and 
third (JSK) authors. The search was completed in August 2014. The electronic databases 
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PubMed, PsychInfo, EMBASE, CINAHL, and HAPI were searched using the following text 
words and their combinations: leukemia or leukaemia and each individual instrument 
included in this study. In a previous acute leukemia literature review conducted by Bryant et 
al4, 20 instruments were identified: Brief Fatigue Inventory (BFI), Center for Epidemiologic 
Studies Depression Scale (CES-D), Distress Thermometer, Edmonton Symptom Assessment 
Scale (ESAS), European Organization for Research and Treatment of Cancer (EORTC 
QLQ-C30), Fatigue Visual Analog Scale (F-VAS), Functional Assessment of Cancer 
Therapy-Fatigue (FACT-F), Functional Assessment of Cancer Therapy-General (FACT-G), 
Functional Assessment of Cancer Therapy-Spiritual (FACT-Sp), Functional Living Index-
Cancer (FLIC), Geriatric Depression Scale (GDS), Hospital and Anxiety Scale (HADS), 
Life Ingredient Profile (LIP), Mental Adjustment to Cancer (MAC), the M.D. Anderson 
Symptom Inventory (MDASI), Psychosocial Adjustment to Illness Scale-Self report (PAIS-
SR), Perceived Quality of Life (PQOL), Revised Piper Fatigue Scale (RPFS), Schedule for 
the Evaluation of Individual Quality of Life (SEIQOL), and Short-Form-36 (SF-36). Fifteen 
instruments were removed from the initial review of 20 instruments due to not being clearly 
defined as a symptom or HRQOL domain, lack of testing to determine psychometric 
properties, or the sample did not specifically include adults with acute leukemia. The five 
remaining instruments were BFI7, FACT-F8, FACT-G9, MDASI10, and EORTC QLQ-C3011. 
Two additional instruments were added based on the search strategy: Functional Assessment 
of Cancer Therapy-Anemia (FACT-An)8 and Functional Assessment of Cancer Therapy-
Leukemia (FACT-Leu).5 The final analysis included 7 instruments.
Inclusion and Exclusion Criteria
Studies were considered eligible for inclusion if 1) the psychometric paper was published 
using at least one HRQOL or symptom instrument and 2) adults with acute leukemia were 
included in the sample. Studies were excluded if the age groups were not adults, or if the 
instrument was in a language other than English. Other exclusions included case reviews, 
summary reports, clinical reviews, and literature and systematic reviews.
A total of 1,547 articles were identified through the 5 electronic databases and manual 
searches. Five hundred sixty-nine were duplicates articles, 324 were chronic leukemia, 
myelodysplastic syndrome (MDS), or hematopoietic stem cell transplant (HSCT), 309 were 
about cancer survivors and not acute leukemia, and 290 did not meet the criteria and were 
removed after initial review. Fifty-five full text articles were assessed for eligibility, and 10 
of those were excluded because the studies used non-English instruments, 23 were review or 
case studies, and 11 focused on childhood cancers. Fourteen studies reported use of a 
HRQOL and/or symptom instrument 7,12-24 (Figure 1). Seven instruments were identified 
based on inclusion criteria: 1) Brief Fatigue Inventory (BFI)7, 2) European Organization for 
Research and Treatment of Cancer (EORTC QLQ-C30)11, 3) Functional Assessment of 
Cancer Therapy-Anemia (FACT-An)8, 4) Functional Assessment of Cancer Therapy-Fatigue 
(FACT-F)8, 5) Functional Assessment of Cancer Therapy-General (FACT-G)9, 6) Functional 
Assessment of Cancer Therapy-Leukemia (FACT-Leu)5, and 7) M.D. Anderson Symptom 
Inventory (MDASI)10.
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Data Extraction
Both generic and disease-specific HRQOL aspects of leukemia were identified in this 
review. In addition, the review also yielded symptom instruments which were either solely 
symptom focused or multidimensional with HRQOL domains. The psychometric properties, 
reliability and validity, of each instrument were extracted using the Scientific Advisory 
Committee of the Medical Outcomes Trust criteria.6 Reliability is “the degree to which an 
instrument is free from error” and validity is the “degree to which the instrument measures 
what it purports to measure”6(pg. 3).
Data Synthesis
The findings from the review are in narrative and table form. The different measures 
identified in this review and their complete description such as number of items, scoring, 
domains, scaling, reliability, validity, and numbers of studies are provided in Table 1. The 
number of items and measured domains of all instruments ranged from 10-47 and 5-15, 
respectively. Four instruments measured both symptom and HRQOL domains (FACT-An, 
FACT-F, FACT-Leu and EORTC QLQ-C30). The 14 studies identified in the review are 
described in Table 2.
Validated HRQOL measures used in Adults with Acute Leukemia
A total of 7 instruments (1 cancer generic HRQOL, 2 symptom-related, 3 HRQOL 
combined with symptom questions, and 1 disease-specific) were identified and included in 
this review. The cancer generic HRQOL instrument was the FACT-G.9 The two symptom-
related instruments included the BFI7 and MDASI10. The three HRQOL instruments with 
symptom questions included FACT-An8, FACT-F8, and EORTC-QLQ-C3011. The FACT-
Leu was the only disease-specific instrument.5
Description of Symptom and HRQOL Instruments and their Psychometric Properties
The psychometric properties of the fourteen studies and their use of symptom and HRQOL 
instruments are presented in the Table 2. The symptom measure with the highest number of 
items was MDASI.10 The most commonly used HRQOL measure was the EORTC-QLQ-
C30 measures (physical, role, social and emotional function, cognitive, financial impact, and 
global QOL).
The number of items and domains in the symptom instruments ranged from 1-13 and 1-6. 
The BFI recall period was in the “past 24 hours,”7 MDASI recall period was the “last 24 
hours,”10 and FACT instruments were in the “last 7 days”5,8-9. All the HRQOL instruments 
reviewed in this study report overall internal consistency reliability in the range of .54-.96 
and test-retest reliability ranging from .77-96. Content and convergent validity were reported 
for all measures.
Description of Identified Studies
The fourteen studies included in this review were of several types: one was a prospective, 
cross-sectional study, two were tool validation studies, two were prospective observational 
studies, four were exercise interventions, and five were prospective longitudinal studies. Ten 
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of the studies included only patients with acute leukemia, one included patients with acute 
and chronic leukemia and the other three studies included patients of various cancer types. 
(Table 2). Stage of cancer treatment was not included because of the variety of cancer types 
and treatments patients were undergoing. The average number of patients in each of these 
studies was 104 (range 10-595). All studies were published between 1998-2012.
Discussion
This study reviewed the published psychometric literature and described 7 instruments that 
measured symptoms or HRQOL in adults with acute leukemia. There is no universally 
accepted definition of QOL/HRQOL, but various organizations and researchers have defined 
it as multidimensional in nature. In 2005, the World Health Organization (WHO)25 defined 
QOL as “an individual's perception of their position in life, in the context of the culture and 
value systems in their life, and in relation to their goals, expectations, standards and 
concerns.”25 Cella's26 definition of HRQOL refers to the extent to which one's usual or 
expected physical, emotional, and social well-being are affected by a medical condition or 
its treatment, whereas Ferrell's QOL framework27 includes physical, psychological, social, 
and spiritual domains. Consideration of these QOL domains is necessary in understanding 
the impact of an acute leukemia treatment and the long term and late effects that accompany 
this diagnosis.
While using the Scientific Advisory Committee of the Medical Outcomes Trust guidelines28, 
we assessed the HRQOL instruments using the attributes and criteria that focus on 
reliability, validity, cultural and language adaptations. We did assess cultural and language 
adaptations and noted many of these instruments had been translated and adapted in several 
languages. One challenge faced by researchers and clinicians is use of reliable and valid 
measures during and after treatment are responsive to clinical changes. Measures that can 
capture change over time (i.e., an instruments “responsiveness” to change) are ideal and 
allows for comparisons between time points. There are two types of HRQOL measures used 
in this analysis. First, the generic cancer HRQOL measure, FACT-G, is able to measure 
these domains across different cancers. Few instruments are available that measure HRQOL 
domains specific to acute leukemia survivors, with one exception, the FACT-Leu. 
Surprisingly, the FACT-F measure was used more often in these studies than FACT-G or 
FACT-Leu. This may be associated with emerging data on the impact that cancer related 
fatigue (CRF) has on adults with acute leukemia during inpatient treatment12-15,17-18,29-30, 
and CRF being a persistent symptom during and after treatment.3-4,31 The FACT-G and 
EORTC-QLQ-C30 have been validated in a number of cancer groups with a variety of 
translations, compared to the FACT-Leu, which was only recently developed and validated.
Limitations of this review include focus on adults with acute leukemia without searching 
grey literature for additional studies such as dissertation abstracts and letters to the editors. 
We did not focus on chronic leukemias or other hematological cancers, which limits our 
generalizability to other cancers. However, a systematic methodologic approach using 
PRISMA was a strength of this review.
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Conclusions
Acute leukemia researchers, clinicians, and oncology nurses need to have comprehensive 
data to explore clinical changes in their patients' symptom or HRQOL responses. Oncology 
nurses are at the frontline of caring for these patients and it is essential for them to be aware 
of instruments and tools used in acute leukemia research. Their use of these instruments will 
allow for early recognition and identification of common symptoms and/or HRQOL changes 
in these adults. There are certain domains of HRQOL that may be more prominent in acute 
leukemia survivors, such as increased symptoms and decreased functionality.4 To the 
authors' knowledge, this is the first review to explore the psychometric properties of 
instruments used with the acute leukemia adult population.
Our recommendations for clinical use and research are based on this review including a 
using both a HRQOL and symptom instrument to capture patient experiences during and 
after treatment. There are sound, reliable instruments that have been used in this population 
and we believe there are instruments that could adequately measure the patient's symptom 
and HRQOL experience throughout their illness trajectory. However, we question if these 
measures will be relevant over time with longer term survivors? The majority of measures 
have been tested in patients within 2 years of treatment; researchers lack data to support use 
of these measures in longer term survivors (>5 years or longer). Survivorship needs of these 
patients may need to be re-evaluated after 2 years since the late and long term effects may 
differ in each cancer population.
The HRQOL instruments vary in domains but the FACT-Leu has both general and specific 
leukemia questions. None of the current studies identified used the Patient-Reported 
Outcomes Measurement Information System (PROMIS), a promising new system designed 
to validly and reliably measure HRQOL domains in multiple populations; however no 
studies to date have examined the psychometric properties of PROMIS measures in acute 
adult leukemia. This review provides an overall synopsis of previous symptom and HRQOL 
literature in the acute leukemia population.
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Figure 1. PRISMA Flow Diagram
From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS 
Med 6(6): e1000097. doi:10.1371/journal.pmed1000097
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Table 2
Summary of the Studies using Symptoms and HRQOL Instruments in Adults with Acute 
Leukemia (n=14)
Author
Purpose
Study Design Sample Characteristics
Alibhai, Leach et al14 Prospective, longitudinal Total n=65; n=65 acute leukemia
Alibhai, Leach, Kermalli et 
al13
Prospective, longitudinal Total n=65; n=65 acute leukemia
Alibhai et al12 Non-randomized, prospective exercise 
intervention
Total n=35; n=35 acute leukemia
Battaglini et al15 Non-randomized exercise intervention Total n=10; n=10 acute leukemia
Cella et al24 Tool validation Total n=29 (item generation), 79 (validation); acute and 
chronic leukemia
Efficace et al16 Prospective, observational Total n=119; mixed cancers
Jarden et al17 Prospective exercise and health counseling trial Total n=17; n=17 acute leukemia
Oliva et al20 Prospective, observational Total n=113; n=113 acute leukemia
Mendoza et al7 Tool validation Total n=595; n=68 acute leukemia
Mohamedali et al19 Prospective, longitudinal cohort Total n=103; n=103 acute leukemia
Pearce et al21 Prospective, cross-sectional Total n=150; mixed cancers
Persson et al22 Prospective, longitudinal Total n=16; mixed cancers
Shabbir et al18 Non-randomized prospective exercise intervention Total n=35; n=35 acute leukemia
Schumacher et al23 Prospective, longitudinal Total n=28; n=28 acute leukemia
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